Evaluating Emerging Evidence and Novel Treatment Approaches for EGFR-Positive NSCLC

Evaluating Emerging Evidence and Novel Treatment Approaches for EGFR-Positive NSCLC

This second webinar of the Hot Topics in Lung Cancer series dives into cutting-edge strategies for managing EGFR-positive non-small cell lung cancer (NSCLC). Join us to explore the latest therapeutic advancements and emerging options for EGFR-targeted. Attendees will gain a deeper understanding of the mechanisms of action of EGFR inhibitors through an engaging whiteboard animation, providing a clear view of how these therapies target EGFR mutations. The session will conclude with expert discussions on integrating EGFR-targeted treatments into clinical practice to optimize patient outcomes.

  • Provider:PRIME Education, Inc. (PRIME®)
  • Activity Link: https://primeinc.org/virtual/evaluating-emerging-evidence-novel-treatment-approaches-egfr-positive-nsclc
  • Start Date: 2025-04-02 05:00:00
  • End Date: 2025-04-02 05:00:00
  • Credit Details: IPCE Credits: 1.0 hours
    AAPA Category 1 Credit™️: 1.0 hours
    AMA PRA Category 1 Credit™️: 1.0 hours
    Nursing: 1.0 hours
    Pharmacy: 1.0 hours
  • Commercial Support: Source: astrazeneca-pharmaceuticals - Amount: 0.0 - Is Kind Support: False Source: daiichi-sankyo,-inc - Amount: 0.0 - Is Kind Support: False Source: lilly-usa-llc - Amount: 0.0 - Is Kind Support: False
  • Activity Type: Live Course
  • CME Finder Type: Conference
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner/Team Competence
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.